Skip to main content
. 2009 Sep 28;30(5):474–480. doi: 10.1159/000242476

Fig. 1.

Fig. 1.

Anti-α3(IV)NC1 mAb bind to human α3(IV)NC1. Human mAb produced from XenoMouse II® after immunization with α3(IV)NC1 preparations bound to human α3(IV)NC1 by Western blot. Greater binding of m anti-α3(IV) to intact human α3(IV)NC1 with lesser binding to reduced human α3(IV)NC1, similar to that observed for human polyclonal serum-derived Ab. 4–6 μg Ag were used in these experiments.